291 related articles for article (PubMed ID: 33428284)
1. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.
Wu LT; John WS; Ghitza UE; Wahle A; Matthews AG; Lewis M; Hart B; Hubbard Z; Bowlby LA; Greenblatt LH; Mannelli P;
Addiction; 2021 Jul; 116(7):1805-1816. PubMed ID: 33428284
[TBL] [Abstract][Full Text] [Related]
2. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.
Wu LT; John WS; Morse ED; Adkins S; Pippin J; Brooner RK; Schwartz RP
Addiction; 2022 Feb; 117(2):444-456. PubMed ID: 34286886
[TBL] [Abstract][Full Text] [Related]
3. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
DiPaula BA; Menachery E
J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
[TBL] [Abstract][Full Text] [Related]
4. Communication Experiences of DATA-Waivered Physicians with Community Pharmacists: A Qualitative Study.
Ventricelli DJ; Mathis SM; Foster KN; Pack RP; Tudiver F; Hagemeier NE
Subst Use Misuse; 2020; 55(3):349-357. PubMed ID: 31591924
[No Abstract] [Full Text] [Related]
5. Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations.
McLeman B; Gauthier P; Lester LS; Homsted F; Gardner V; Moore SK; Joudrey PJ; Saldana L; Cochran G; Harris JP; Hefner K; Chongsi E; Kramer K; Vena A; Ottesen RA; Gallant T; Boggis JS; Rao D; Page M; Cox N; Iandiorio M; Ambaah E; Ghitza U; Fiellin DA; Marsch LA
Addict Sci Clin Pract; 2024 Mar; 19(1):18. PubMed ID: 38500166
[TBL] [Abstract][Full Text] [Related]
6. Improving access to care via psychiatric clinical pharmacist practitioner collaborative management of buprenorphine for opioid use disorder.
Pals H; Bratberg J
J Am Pharm Assoc (2003); 2022; 62(4):1422-1429. PubMed ID: 35365405
[TBL] [Abstract][Full Text] [Related]
7. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
[TBL] [Abstract][Full Text] [Related]
8. The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States.
Stringfellow EJ; Lim TY; Dong H; Zhang Z; Jalali MS
Addiction; 2023 Nov; 118(11):2215-2219. PubMed ID: 37434347
[TBL] [Abstract][Full Text] [Related]
9. Collaborative care in the treatment of opioid use disorder and mental health conditions in primary care: A clinical study protocol.
Harris RA; Mandell DS; Kampman KM; Bao Y; Campbell K; Cidav Z; Coviello DM; French R; Livesey C; Lowenstein M; Lynch KG; McKay JR; Oslin DW; Wolk CB; Bogner HR
Contemp Clin Trials; 2021 Apr; 103():106325. PubMed ID: 33631356
[TBL] [Abstract][Full Text] [Related]
10. Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder.
DeRonne BM; Wong KR; Schultz E; Jones E; Krebs EE
Am J Health Syst Pharm; 2021 Feb; 78(4):354-359. PubMed ID: 33326564
[TBL] [Abstract][Full Text] [Related]
11. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
Wen H; Hockenberry JM; Pollack HA
JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
[TBL] [Abstract][Full Text] [Related]
12. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
Textor L; Ventricelli D; Aronowitz SV
Int J Drug Policy; 2022 Jul; 105():103703. PubMed ID: 35561484
[TBL] [Abstract][Full Text] [Related]
13. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
14. A physician-pharmacist collaborative care model to prevent opioid misuse.
Lagisetty P; Smith A; Antoku D; Winter S; Smith M; Jannausch M; Mi Choe H; Bohnert ASB; Heisler M
Am J Health Syst Pharm; 2020 May; 77(10):771-780. PubMed ID: 32315401
[TBL] [Abstract][Full Text] [Related]
15. A bridge too far? Distance to waivered physicians and utilization of buprenorphine treatment for opioid use disorder in West Virginia Medicaid.
Saloner B; Landis RK; Jayakrishnan R; Stein BD; Barry CL
Subst Abus; 2022; 43(1):682-690. PubMed ID: 35099362
[No Abstract] [Full Text] [Related]
16. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders.
Clark B; Kai M; Dix R; White J; Rozenfeld Y; Levy S; Engstrom K
JAMA Netw Open; 2019 Oct; 2(10):e1913818. PubMed ID: 31642929
[TBL] [Abstract][Full Text] [Related]
17. Pharmacist-prescriber collaborative models of care for opioid use disorder: an overview of recent research.
Cheetham A; Grist E; Nielsen S
Curr Opin Psychiatry; 2024 Jul; 37(4):251-257. PubMed ID: 38726819
[TBL] [Abstract][Full Text] [Related]
18. Physicians' satisfaction with providing buprenorphine treatment.
Knudsen HK; Brown R; Jacobson N; Horst J; Kim JS; Collier E; Starr S; Madden LM; Haram E; Toy A; Molfenter T
Addict Sci Clin Pract; 2019 Aug; 14(1):34. PubMed ID: 31446893
[TBL] [Abstract][Full Text] [Related]
19. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
[TBL] [Abstract][Full Text] [Related]
20. Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional survey.
Foti K; Heyward J; Tajanlangit M; Meek K; Jones C; Kolodny A; Alexander GC
Drug Alcohol Depend; 2021 Aug; 225():108811. PubMed ID: 34175786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
